Payment overview · 2025
General Payments
$2,068.50
114 reported records · 28 companies
Healthcare provider profile · identity verified
Kapil Kwatra, M.D
Allopathic & Osteopathic Physicians|Internal Medicine · WARREN, OH · NPI 1326016320
Verified facts
What the public records show
CMS Open Payments records show Kapil Kwatra, M.D received $2,068.50 in general payments during 2025 across 114 reported records.
PFIZER INC. accounted for 12.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 44 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Farxiga, Gemtesa, Jardiance, Mounjaro, Ozempic, Paxlovid, Rexulti, Rybelsus, Vraylar, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 1035 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Wegovy by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1035 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulance by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $251.40 | 12.2% | 17 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $248.08 | 12.0% | 14 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $217.55 | 10.5% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $181.89 | 8.8% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $157.45 | 7.6% | 8 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $115.16 | 5.6% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $110.51 | 5.3% | 7 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $93.95 | 4.5% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $84.52 | 4.1% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $77.31 | 3.7% | 4 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $60.91 | 2.9% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $54.25 | 2.6% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $43.94 | 2.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $43.52 | 2.1% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $41.14 | 2.0% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $37.89 | 1.8% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $37.48 | 1.8% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $26.43 | 1.3% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $24.36 | 1.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.70 | 1.1% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $21.83 | 1.1% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.12 | 1.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.02 | 1.0% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $15.56 | 0.8% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.30 | 0.7% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $15.17 | 0.7% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $14.94 | 0.7% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $14.12 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,026.00 | 113 |
| Education | $42.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $209.90 | 12 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $197.03 | 12 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $171.26 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $165.81 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $159.10 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $143.54 | 10 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $117.86 | 8 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $115.16 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $110.51 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $110.51 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $106.85 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $105.10 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $84.89 | 5 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $71.16 | 6 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $68.95 | 4 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $60.91 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $54.25 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $54.00 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $52.99 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $51.65 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $43.94 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $43.52 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $41.14 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $37.89 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $37.48 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $36.96 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $26.43 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $24.36 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.70 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $21.83 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.14 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.14 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.14 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $20.33 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $20.11 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.10 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| EVKEEZA Normalized: evkeeza |
Biological | Regeneron Healthcare Solutions, Inc. | $15.56 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $15.17 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $14.94 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $14.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1035 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 128 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 72 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 185 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 192 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 133 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 25 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
59 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
124 | 34 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
96 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
72 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
185 | 45 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1035 | 129 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
185 | 45 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
192 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
96 | 18 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
128 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
133 | 32 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1035 | 129 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
25 | 24 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1963 | 352 |
| Amlodipine Besylate | Amlodipine Besylate | 1673 | 443 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1567 | 315 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1237 | 210 |
| Furosemide | Furosemide | 1149 | 226 |
| Eliquis | Apixaban | 1035 | 129 |
| Losartan Potassium | Losartan Potassium | 810 | 197 |
| Metoprolol Succinate | Metoprolol Succinate | 793 | 213 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 717 | 220 |
| Gabapentin | Gabapentin | 698 | 159 |
| Omeprazole | Omeprazole | 681 | 183 |
| Potassium Chloride | Potassium Chloride | 680 | 136 |
| Metoprolol Tartrate | Metoprolol Tartrate | 640 | 155 |
| Lisinopril | Lisinopril | 610 | 156 |
| Tramadol Hcl | Tramadol Hcl | 601 | 111 |
| Metformin Hcl | Metformin Hcl | 586 | 149 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 555 | 99 |
| Simvastatin | Simvastatin | 555 | 144 |
| Donepezil Hcl | Donepezil Hcl | 529 | 59 |
| Meloxicam | Meloxicam | 521 | 167 |
| Tamsulosin Hcl | Tamsulosin Hcl | 496 | 124 |
| Sertraline Hcl | Sertraline Hcl | 448 | 92 |
| Lorazepam | Lorazepam | 443 | 83 |
| Clopidogrel | Clopidogrel Bisulfate | 381 | 104 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 376 | 39 |
| Glimepiride | Glimepiride | 365 | 94 |
| Allopurinol | Allopurinol | 339 | 78 |
| Prednisone | Prednisone | 329 | 158 |
| Divalproex Sodium | Divalproex Sodium | 314 | 46 |
| Atenolol | Atenolol | 302 | 68 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 289 | 55 |
| Alprazolam | Alprazolam | 257 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 257 | 67 |
| Trazodone Hcl | Trazodone Hcl | 256 | 54 |
| Memantine Hcl | Memantine Hcl | 250 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 234 | 46 |
| Montelukast Sodium | Montelukast Sodium | 201 | 63 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 197 | 52 |
| Mounjaro | Tirzepatide | 192 | 34 |
| Jardiance | Empagliflozin | 185 | 45 |
| Carvedilol | Carvedilol | 184 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 184 | 87 |
| Buspirone Hcl | Buspirone Hcl | 182 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 180 | 42 |
| Hydralazine Hcl | Hydralazine Hcl | 179 | 49 |
| Warfarin Sodium | Warfarin Sodium | 171 | 36 |
| Citalopram Hbr | Citalopram Hydrobromide | 168 | 36 |
| Methylprednisolone | Methylprednisolone | 168 | 136 |
| Doxycycline Hyclate | Doxycycline Hyclate | 166 | 110 |
| Pravastatin Sodium | Pravastatin Sodium | 166 | 47 |
| Mirtazapine | Mirtazapine | 161 | 33 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 156 | 41 |
| Azithromycin | Azithromycin | 155 | 130 |
| Clonazepam | Clonazepam | 152 | 35 |
| Finasteride | Finasteride | 143 | 40 |
| Xarelto | Rivaroxaban | 143 | 19 |
| Levetiracetam | Levetiracetam | 138 | 22 |
| Alendronate Sodium | Alendronate Sodium | 137 | 38 |
| Famotidine | Famotidine | 136 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 135 | 68 |
| Ozempic | Semaglutide | 133 | 32 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 130 | 30 |
| Entresto | Sacubitril/Valsartan | 128 | 22 |
| Colchicine | Colchicine | 127 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 127 | 35 |
| Ezetimibe | Ezetimibe | 126 | 38 |
| Synthroid | Levothyroxine Sodium | 124 | 34 |
| Oxycodone Hcl | Oxycodone Hcl | 123 | 25 |
| Amiodarone Hcl | Amiodarone Hcl | 116 | 27 |
| Levofloxacin | Levofloxacin | 113 | 98 |
| Fluoxetine Hcl | Fluoxetine Hcl | 112 | 22 |
| Olanzapine | Olanzapine | 112 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 111 | 98 |
| Ropinirole Hcl | Ropinirole Hcl | 109 | 15 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 107 | 33 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 105 | 84 |
| Spironolactone | Spironolactone | 103 | 31 |
| Methotrexate | Methotrexate Sodium | 102 | 12 |
| Bumetanide | Bumetanide | 99 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 97 | 29 |
| Digoxin | Digoxin | 96 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 96 | 31 |
| Myrbetriq | Mirabegron | 96 | suppressed |
| Trulicity | Dulaglutide | 96 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 93 | 36 |
| Clonidine Hcl | Clonidine Hcl | 90 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 87 | 21 |
| Ketoconazole | Ketoconazole | 85 | 33 |
| Oxybutynin Chloride | Oxybutynin Chloride | 85 | 24 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 84 | 11 |
| Fentanyl | Fentanyl | 82 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 80 | 18 |
| Propranolol Hcl | Propranolol Hcl | 78 | 16 |
| Glipizide | Glipizide | 73 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 73 | 44 |
| Pregabalin | Pregabalin | 73 | 13 |
| Baclofen | Baclofen | 72 | 19 |
| Farxiga | Dapagliflozin Propanediol | 72 | 16 |
| Torsemide | Torsemide | 72 | 18 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 71 | 17 |
| Januvia | Sitagliptin Phosphate | 70 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 69 | 43 |
| Meclizine Hcl | Meclizine Hcl | 68 | 41 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 68 | 18 |
| Benazepril Hcl | Benazepril Hcl | 65 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 65 | 35 |
| Metformin Hcl Er | Metformin Hcl | 64 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 64 | 13 |
| Sucralfate | Sucralfate | 64 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 63 | 18 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 63 | 27 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 60 | 11 |
| Lactulose | Lactulose | 59 | 14 |
| Linzess | Linaclotide | 59 | 14 |
| Megestrol Acetate | Megestrol Acetate | 58 | 17 |
| Budesonide | Budesonide | 57 | 11 |
| Cephalexin | Cephalexin | 57 | 44 |
| Midodrine Hcl | Midodrine Hcl | 57 | 18 |
| Brilinta | Ticagrelor | 56 | suppressed |
| Celecoxib | Celecoxib | 56 | 15 |
| Diltiazem Hcl | Diltiazem Hcl | 55 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 55 | suppressed |
| Nystatin | Nystatin | 55 | 32 |
| Tradjenta | Linagliptin | 55 | suppressed |
| Dexamethasone | Dexamethasone | 54 | 43 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 54 | 24 |
| Diazepam | Diazepam | 53 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | 21 |
| Fenofibrate | Fenofibrate Nanocrystallized | 52 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 51 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 50 | suppressed |
| Latanoprost | Latanoprost | 49 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 29 |
| Primidone | Primidone | 47 | suppressed |
| Fenofibrate | Fenofibrate | 46 | 14 |
| Morphine Sulfate Er | Morphine Sulfate | 46 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | 11 |
| Amoxicillin | Amoxicillin | 45 | 32 |
| Gemfibrozil | Gemfibrozil | 45 | 11 |
| Levemir Flexpen | Insulin Detemir | 45 | suppressed |
| Rexulti | Brexpiprazole | 45 | suppressed |
| Bupropion Xl | Bupropion Hcl | 44 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 44 | 15 |
| Ibuprofen | Ibuprofen | 43 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 43 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 41 | suppressed |
| Lamotrigine | Lamotrigine | 40 | suppressed |
| Haloperidol | Haloperidol | 39 | suppressed |
| Jantoven | Warfarin Sodium | 39 | 15 |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 39 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 38 | suppressed |
| Fluconazole | Fluconazole | 37 | 26 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 37 | suppressed |
| Novolog Flexpen | Insulin Aspart | 37 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 37 | 11 |
| Methocarbamol | Methocarbamol | 35 | 14 |
| Hydrocortisone | Hydrocortisone | 34 | 15 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 33 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Mupirocin | Mupirocin | 33 | 25 |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 32 | 11 |
| Glipizide Er | Glipizide | 32 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 31 | 22 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 31 | suppressed |
| Temazepam | Temazepam | 31 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 30 | 20 |
| Vraylar | Cariprazine Hcl | 30 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 29 | 21 |
| Memantine Hcl Er | Memantine Hcl | 28 | suppressed |
| Methimazole | Methimazole | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | 13 |
| Rybelsus | Semaglutide | 27 | suppressed |
| Verapamil Er | Verapamil Hcl | 27 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 18 |
| Quviviq | Daridorexant Hcl | 26 | suppressed |
| Risperidone | Risperidone | 26 | suppressed |
| Rivastigmine | Rivastigmine | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 25 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Mesalamine | Mesalamine | 25 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 24 |
| Restasis | Cyclosporine | 25 | suppressed |
| Sotalol | Sotalol Hcl | 25 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Metronidazole | Metronidazole | 23 | 17 |
| Ramipril | Ramipril | 23 | suppressed |
| Repatha Sureclick | Evolocumab | 23 | suppressed |
| Carbamazepine Er | Carbamazepine | 22 | suppressed |
| Glyburide | Glyburide | 22 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 22 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 22 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Nystop | Nystatin | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Cefdinir | Cefdinir | 19 | 17 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 19 | suppressed |
| Creon | Lipase/Protease/Amylase | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Estradiol | Estradiol | 17 | 11 |
| Lidocaine | Lidocaine | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 17 | 14 |
| Trulance | Plecanatide | 17 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 16 | 16 |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Praluent Pen | Alirocumab | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Wegovy | Semaglutide | 15 | suppressed |
| Belsomra | Suvorexant | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Cimetidine | Cimetidine | 14 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 14 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Ursodiol | Ursodiol | 14 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Orencia Clickject | Abatacept | 13 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 13 | suppressed |
| Acetylcysteine | Acetylcysteine | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Phenytek | Phenytoin Sodium Extended | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Acetazolamide | Acetazolamide | 11 | suppressed |
| Arformoterol Tartrate | Arformoterol Tartrate | 11 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Constulose | Lactulose | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Propafenone Hcl Er | Propafenone Hcl | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,068.50 · 114 records | PFIZER INC. | ABRYSVO, AFREZZA, AIRSUPRA, AUSTEDO XR, Auvelity, BREZTRI, CAMZYOS, CAPLYTA, CAPVAXIVE, COMIRNATY, ELIQUIS, ENTRESTO, EVKEEZA, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, IBSRELA, JARDIANCE, KISUNLA, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, UNITHROID, VERQUVO, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, YUPELRI, ZAVZPRET, ZEPBOUND | 23 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error